Monday, December 9th | 12 Kislev 5780

Subscribe
October 20, 2019 7:46 am

Pharma Company Cosmo Takes 22 Percent Stake in Israeli Gastro Treatment Company Redhill

avatar by Tzally Greenberg / CTech

Assorted pharmaceuticals. Photo: LadyofProcrastination via Flickr.

CTech – Ireland-headquartered Cosmo Pharmaceuticals is acquiring a 21.8 percent stake in Nasdaq and Tel Aviv-listed pharmaceutical company RedHill Biopharma, the latter announced in a stock exchange filing Friday. The deal will make Cosmo Redhill’s largest shareholder.

Under the agreement, Redhill will pay Cosmo the stock equivalent of $12 million, which comes up to 5.9 percent of Redhill’s shares, for exclusive commercialization rights in the US of Cosmo’s Aemcolo for Traveler’s Diarrhea. Redhill has agreed to pay Cosmo up to $100 million dependent on related milestones, as well as royalties. Cosmo will also pay Redhill $36.3 million for 15.9 percent of Redhill’s shares, pricing them at $7 per share, a 13.5 percent premium on the company’s price on Thursday’s close.

Founded in 2009, Tel Aviv-headquartered RedHill develops orally-administered medicine for gastrointestinal and inflammatory diseases. RedHill is traded at a market capitalization of around $180 million, as of market close Friday.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.